

## SUPPLEMENTARY REFERENCES

- S1. A.C. Heijboer, M.A. Blankenstein, J. Hoenderop, et al., Laboratory aspects of circulating alpha-Klotho, *Nephrol Dial Transplant* **28**, 2013, 2283-2287.
- S2. D. Zou, W. Wu, Y. He, et al., The role of klotho in chronic kidney disease, *BMC Nephrol* **19**, 2018, 285.
- S3. S.F. Nagueh, O.A. Smiseth, C.P. Appleton, et al., Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging, *J Am Soc Echocardiogr* **29**, 2016, 277-314.
- S4. C. Faul, A. P. Amaral, B. Oskouei, et al., FGF23 induces left ventricular hypertrophy, *J Clin Invest* **121**, 2011, 4393-4408.
- S5. J. Xie, J. Yoon, S. W. An, et al., Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate, *J Am Soc Nephrol* **26**, 2015, 1150-1160.